重编程
转录因子
细胞命运测定
细胞生物学
生物
细胞分化
诱导多能干细胞
再生医学
染色质免疫沉淀
染色质
电池类型
干细胞
细胞
遗传学
基因表达
胚胎干细胞
基因
发起人
作者
Maria A. Missinato,Sean Murphy,Michaela Lynott,Michael S. Yu,Anaïs Kervadec,Yu-Ling Chang,Suraj Kannan,Mafalda Loreti,Christopher Lee,Prashila Amatya,Hiroshi Tanaka,Chun‐Teng Huang,Prem Puri,Chulan Kwon,Peter D. Adams,Qian Li,Alessandra Sacco,Peter Andersen,Alexandre R. Colas
标识
DOI:10.1038/s41467-023-37256-8
摘要
Abstract Defining the mechanisms safeguarding cell fate identity in differentiated cells is crucial to improve 1) - our understanding of how differentiation is maintained in healthy tissues or altered in a disease state, and 2) - our ability to use cell fate reprogramming for regenerative purposes. Here, using a genome-wide transcription factor screen followed by validation steps in a variety of reprogramming assays (cardiac, neural and iPSC in fibroblasts and endothelial cells), we identified a set of four transcription factors (ATF7IP, JUNB, SP7, and ZNF207 [AJSZ]) that robustly opposes cell fate reprogramming in both lineage and cell type independent manners. Mechanistically, our integrated multi-omics approach (ChIP, ATAC and RNA-seq) revealed that AJSZ oppose cell fate reprogramming by 1) - maintaining chromatin enriched for reprogramming TF motifs in a closed state and 2) - downregulating genes required for reprogramming. Finally, KD of AJSZ in combination with MGT overexpression, significantly reduced scar size and improved heart function by 50%, as compared to MGT alone post-myocardial infarction. Collectively, our study suggests that inhibition of barrier to reprogramming mechanisms represents a promising therapeutic avenue to improve adult organ function post-injury.
科研通智能强力驱动
Strongly Powered by AbleSci AI